KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $377.9 million.

  • Alnylam Pharmaceuticals' Net Cash Flow rose 22515.4% to $377.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $366.9 million, marking a year-over-year increase of 57502.71%. This contributed to the annual value of $169.0 million for FY2024, which is 38138.29% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Net Cash Flow stood at $377.9 million for Q3 2025, which was up 22515.4% from $66.1 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Net Cash Flow high stood at $495.6 million for Q3 2022, and its period low was -$283.7 million during Q1 2022.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Net Cash Flow value was $39.5 million (recorded in 2025), while the average stood at $51.5 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first tumbled by 870126.54% in 2021, then soared by 212442.5% in 2024.
  • Over the past 5 years, Alnylam Pharmaceuticals' Net Cash Flow (Quarter) stood at -$271.3 million in 2021, then grew by 23.15% to -$208.5 million in 2022, then decreased by 10.92% to -$231.2 million in 2023, then surged by 49.58% to -$116.6 million in 2024, then surged by 424.14% to $377.9 million in 2025.
  • Its last three reported values are $377.9 million in Q3 2025, $66.1 million for Q2 2025, and $39.5 million during Q1 2025.